140 related articles for article (PubMed ID: 31727329)
21. Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab.
Muether PS; Hermann MM; Viebahn U; Kirchhof B; Fauser S
Ophthalmology; 2012 Oct; 119(10):2082-6. PubMed ID: 22920670
[TBL] [Abstract][Full Text] [Related]
22. Quantitative analysis of central visual field defects in macular edema using three-dimensional computer-automated threshold Amsler grid testing.
Jivrajka RV; Kim JK; Fink W; Sadun AA; Sebag J
Graefes Arch Clin Exp Ophthalmol; 2009 Feb; 247(2):165-70. PubMed ID: 18958487
[TBL] [Abstract][Full Text] [Related]
23. [Visual self-assessment with the ACTO test during follow-up of AMD patients after intravitreal injections].
Cordes A; Strobel A; Meyer CH; Ender F; Schrage N
Ophthalmologe; 2009 Sep; 106(9):775-82. PubMed ID: 19806381
[TBL] [Abstract][Full Text] [Related]
24. [Age-related macular degeneration diagnosis].
Maugetfaÿsse M; Wolff B; Sahel JA; Mathis T
Rev Prat; 2017 Jan; 67(1):92-95. PubMed ID: 30512446
[TBL] [Abstract][Full Text] [Related]
25. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration.
Eyetech Study Group
Retina; 2002 Apr; 22(2):143-52. PubMed ID: 11927845
[TBL] [Abstract][Full Text] [Related]
26. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
[TBL] [Abstract][Full Text] [Related]
27. Two year outcome in treatment-naive patients with neovascular age-related macular degeneration (nAMD) using an individualized regimen of Aflibercept.
Barakat A; Rufin V; Tran THC
J Fr Ophtalmol; 2018 Sep; 41(7):603-610. PubMed ID: 30166233
[TBL] [Abstract][Full Text] [Related]
28. Reliability of self-measurement of visual acuity in AMD patients with two electronic devices based on the ETDRS chart: A randomized study.
Queguiner F; Bezirganyan K; Courjaret JC; Curel L; Penaranda G; Bonomini J; Righini Chossegros M
J Fr Ophtalmol; 2024 Jan; 47(1):103911. PubMed ID: 37648551
[TBL] [Abstract][Full Text] [Related]
29. [Epidemiological and clinical profile of age-related macular degeneration in Cameroon].
Koki G; Nomo A; Ghemmogne Takam C; Biangoup Nyamsi P; Epée E; Ndoye Roth PA; Bella AL
J Fr Ophtalmol; 2022 Mar; 45(3):344-351. PubMed ID: 35093260
[TBL] [Abstract][Full Text] [Related]
30. Increased choroidal thickness: a new feature to monitor age-related macular degeneration recurrence.
Bouteleux V; Kodjikian L; Mendes M; Agard E; Machkour-Bentaleb Z; El-Chehab H; Denis P; Mathis T; Dot C
Graefes Arch Clin Exp Ophthalmol; 2019 Apr; 257(4):699-707. PubMed ID: 30554268
[TBL] [Abstract][Full Text] [Related]
31. Association of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy With Risk of Stroke, Myocardial Infarction, and Death in Patients With Exudative Age-Related Macular Degeneration.
Dalvin LA; Starr MR; AbouChehade JE; Damento GM; Garcia M; Shah SM; Hodge DO; Meissner I; Bakri SJ; Iezzi R
JAMA Ophthalmol; 2019 May; 137(5):483-490. PubMed ID: 30703203
[TBL] [Abstract][Full Text] [Related]
32. Microperimetric changes after intravitreal bevacizumab injection for exudative age-related macular degeneration.
Ozdemir H; Karacorlu M; Senturk F; Karacorlu SA; Uysal O
Acta Ophthalmol; 2012 Feb; 90(1):71-5. PubMed ID: 20163371
[TBL] [Abstract][Full Text] [Related]
33. Age-related macular degeneration and risk factors for the development of choroidal neovascularisation in the fellow eye: a 3-year follow-up study.
Silva R; Cachulo ML; Fonseca P; Bernardes R; Nunes S; Vilhena N; Faria de Abreu JR
Ophthalmologica; 2011; 226(3):110-8. PubMed ID: 21822000
[TBL] [Abstract][Full Text] [Related]
34. [A "fast track" to improve management of neovascular age related macular degeneration].
Krivosic V; Philippakis E; Couturier A; Dupas B; Erginay A; Desmettre T; Streho M; Bonnin S; Mane V; Jouvaud S; Gualino V; Durand D; Tadayoni R
J Fr Ophtalmol; 2017 Oct; 40(8):642-647. PubMed ID: 28865938
[TBL] [Abstract][Full Text] [Related]
35. [Exudative age-related macular degeneration: self-monitoring by patients allows for rapid response].
Girmens JF
Rev Prat; 2017 Jan; 67(1):101. PubMed ID: 30512448
[No Abstract] [Full Text] [Related]
36. Intravitreal aflibercept for ranibizumab-resistant exudative age-related macular degeneration with choroidal vascular hyperpermeability.
Nomura Y; Yanagi Y
Jpn J Ophthalmol; 2015 Jul; 59(4):261-5. PubMed ID: 25983109
[TBL] [Abstract][Full Text] [Related]
37. Home vision monitoring in patients with maculopathy: Real-life study of the OdySight application.
Guigou S; Michel T; Mérité PY; Coupier L; Meyer F
J Fr Ophtalmol; 2021 Jun; 44(6):873-881. PubMed ID: 34024655
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic accuracy of the Amsler grid and the preferential hyperacuity perimetry in the screening of patients with age-related macular degeneration: systematic review and meta-analysis.
Faes L; Bodmer NS; Bachmann LM; Thiel MA; Schmid MK
Eye (Lond); 2014 Jul; 28(7):788-96. PubMed ID: 24788016
[TBL] [Abstract][Full Text] [Related]
39. Exudative age-related macular degeneration or Best vitelliform macular dystrophy?--A case report.
Kubicka-Trzaska A; Filemonowicz-Skoczek A; Karska-Basta I; Romanowska-Dixon B
Klin Oczna; 2008; 110(4-6):183-7. PubMed ID: 18655458
[TBL] [Abstract][Full Text] [Related]
40. Intravitreal bevacizumab treatment for exudative age-related macular degeneration with good visual acuity.
Axer-Siegel R; Bor E; Bourla DH; Weinberger D; Mimouni K
Retina; 2012 Oct; 32(9):1811-20. PubMed ID: 22825407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
